- In February 2023, Insilico Medicine, a clinical-stage end-to-end generative artificial intelligence (AI)-driven drug discovery company, received FDA Orphan Drug Designation for its AI-developed drug aimed at treating idiopathic pulmonary fibrosis, showcasing the transformative potential of AI in addressing rare and unmet medical needs
- In February 2023, Evotec SE expanded its strategic collaboration with Related Sciences, extending their integrated, multi-target drug discovery agreement through 2030, leveraging Evotec’s expertise across the drug development pipeline to accelerate a broad portfolio of innovative therapeutics
- In April 2022, Iktos, a key provider of artificial intelligence solutions for drug design, partnered with Teijin Pharma Limited to advance AI-driven approaches in small molecule drug discovery, emphasizing the growing role of AI in improving drug development speed and therapeutic efficacy
- In January 2022, Shanghai Fosun Pharmaceutical formed a partnership with Insilico Medicine to incorporate AI technologies into its drug discovery and development efforts, reflecting the industry's increasing embrace of AI to enhance pharmaceutical research and streamline the R&D process
